Saturday August 19th 2017

Seasonal Vitamin D Changes and the Impact on Health Risk Assessment.

CONCLUSION: This retrospective epidemiological study demonstrates seasonal variation of vitamin D levels at clinical decision points. Although not unexpected, this variation has an impact on studies relating low vitamin D levels to higher rates of cancer, cardiovascular disease, multiple sclerosis, diabetes, autoimmune disease, and a host of other health risk assessments. PMID: 24525255 [PubMed – as supplied by publisher] (Source: Clinical Biochemistry)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Visit site:

Seasonal Vitamin D Changes and the Impact on Health Risk Assessment.

Leave a Comment

More from category

Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re
Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re

/About-the-Society/News/Researchers-Co-funded-by-National-MS-Society-Repor [Read More]

Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS
Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

/About-the-Society/News/Investigators-Recruiting-for-Study-of-ALKS-8700-vs [Read More]

Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS
Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS

/About-the-Society/News/Statement-on-House-Oversight-and-Government-Reform [Read More]

Drug blocked by regulators found to improve quality of life for MS patients
Drug blocked by regulators found to improve quality of life for MS patients

A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with [Read More]

House Dems launch MS drug pricing probe
House Dems launch MS drug pricing probe

Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of [Read More]